Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.

ABSTRACT:

Context

Latent tuberculosis infection diagnosis and treatment is a strategic priority for eliminating tuberculosis in the U.S. The Centers for Disease Control and Prevention has recommended the short-course regimen of 3-month isoniazid-rifapentine administered by directly observed therapy. However, longer-duration regimens remain the most widely prescribed latent tuberculosis infection treatments. Limitation on adoption of 3-month isoniazid-rifapentine in the U.S. might be because of patients' preference for self-administered therapy, providers' lack of familiarity with 3-month isoniazid-rifapentine, or lack of resources to support directly observed therapy. This review examines the most recent evidence regarding 3-month isoniazid-rifapentine's effectiveness, safety, and treatment

SUBMITTER: Njie GJ 

PROVIDER: S-EPMC6097523 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature